When to Start HIV Treatment? Which Treatments to Start?

Size: px
Start display at page:

Download "When to Start HIV Treatment? Which Treatments to Start?"

Transcription

1 When to Start HIV Treatment? Which Treatments to Start? Calvin Cohen MD Harvard Medical School Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston USA

2 When to start HIV treatment Late clinical stages Early clinical stages < 200 > 500 High viral load Any viral load CD4 Adapted from Schechter M, JID 2004;190:

3 Four Questions for Deciding When to Start Is there damage done by waiting to start treatment for patients with high T4 counts e.g., >500/mm 3? If yes, is the damage done by delaying HIV treatment completely reversible? At what CD4 count does the damage become irreversible? Are HIV treatments sufficiently ideal to treat everyone who is willing even those at very low risk of HIV-related illness?

4 Years lived Current Life Expectancy of HIV-Positive Patients Comparison of life expectancy of Athena cohort patients (n=4,174) to general population Years of Life Remaining Age at time of death Remaining Life Years General Population Asymptomatic HIV+ Patients Age at 24 weeks (years) van Sighem A, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 526.

5 CIPRAHT001: Randomized Trial of When to Start ART: Haiti Randomized clinical endpoint study of when to start therapy Treatment-naive No hx AIDS-defining illness CD (n=816) Early Treatment (Immediate ZDV/3TC + EFV) Standard Treatment (Delay until CD4+ <200 or AIDS Primary endpoint: Survival Baseline Characteristics Early (n=408) Standard (n=408) Median age (years) Male (%) 41% 44% Median CD4+ (cells/mm 3 ) May 2009: DSMB review stopped study due to excess deaths in Standard Treatment arm Severe P, et al. 49 th ICAAC; San Francisco, CA; Sept , 2009; Abst. H-1230c.

6 CIPRAHT001: Clinical Endpoints Clinical Endpoints Early Rx Standard Hazard Ratio (p value) Death (.0011 ) Incident Tuberculosis (.0125 ) Infectious causes of death Early: 1 (gastroenteritis) Standard: 17 (7 gastroenteritis, 5 TB, 4 pneumonia, 1 cholangitis/sepsis) Severe P, et al. 49 th ICAAC; San Francisco, CA; Sept , 2009; Abst. H-1230c.

7 EACS Guidelines: When to Start ARV Therapy In serodiscordant couples early initiation of ART as one aspect of the overall strategy to reduce HIV transmission to the seronegative partner should be considered and actively discussed Condition C = CONSIDER. D = DEFER. R = RECOMMENDED Current CD4 + lymphocyte count >500 Asymptomatic HIV infection C D Symptomatic HIV disease (CDC B or C conditions) incl. tuberculosis R R Primary HIV infection C C Conditions (likely or possibly) associated with HIV, other than CDC stage B or C disease: HIV-associated kidney disease R R HIV-associated neurocognitive impairment R R Hodgkin's lymphoma R R HPV-associated cancers R R Other non-aids-defining cancers requiring chemo- and/or radiotherapy C C Autoimmune disease otherwise unexplained C C High risk for CVD (>20% estimated 10 yr risk) or history of CVD C C (October, 2011)

8 2011 DHHS Guidelines: Recommendations for Initiation of ART in Naïve Patients Clinical Category CD4 Cell Count (cells/mm 3 ) 2009 DHHS Guidelines Strength-Quality AIDS-defining illness Any value Treat <350 Treat A-I Asymptomatic 350 to 500 Treat A/B-II: 55% A vs. 45% B >500 Treat/Optional B/C-III: 50% B vs. 50% C Pregnancy, HIVassociated nephropathy, HIV/HBV when HBV treatment indicated Any value Treat A-III Note: HIV RNA >100,000 c/ml and decline of CD4+ count > 100 cells/mm 3 per year favor starting ART Strength of Recommendation: A = Strong; B = Moderate; C = Optional Quality of Evidence for Recommendation: I = data from randomized controlled trials; II = data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = expert opinion Available at: Revision December 1, 2009.

9 IAS-USA 2010: Guidelines for When to Start ARV Therapy Measure Specific conditions Symptomatic HIV disease Pregnancy High HIV-1 RNA Level (>100,000 copies/ml) Rapid CD4 count decline (>100 cells/mm 3 per year) Active hepatitis B or C* virus co-infection Active or high risk for cardiovascular disease* HIV-associated nephropathy Symptomatic primary HIV infection* Age > 60* Recommendation ART recommended regardless of CD4 cell count Risk for secondary HIV transmission is high* CD4 cell count 500 cells/mm 3 ART recommended CD4 cell count >500 cells/mm 3 ART should be considered * Differs from 2009 DHHS guidelines Unless patient is an elite controller (HIV-1 RNA <50 copies/ml) or has stable CD4 cell count and low-level viremia in the absence of ART Thompson MA, et al. JAMA 2010;304(3): ; US Department of Health and Human Services Guidelines; Revised December 1, Available at:

10 Results of Three Large Observational Cohorts At what CD4 count does evidence of clinical harm (incr. risk of AIDS and/or death) begin when deferring starting Antiretroviral Therapy? ART-CC: < 350/mm 3 Cascade: < 500/mm 3 NA-ACCORD: Any delay, including > 500/mm 3 Sterne J, at al. 16th CROI; 2009; Montreal. Abstract 72LB., Funk MJ, et al. 18th IAC; Vienna, July 18-23, 2010; Abst. THLBB201., Kitahata M, et al. New Engl J Med 2009;360:

11 Cum. Probability (X100) SMART Naïve/Off Treatment Sub-study: Clinical Outcomes of (re-)starting ARVs Opportunistic disease and death Hazard Ratio = 4.38 (95%.CI: ) p=0.009 Deferred ART Immediate ART Composite endpoint Hazard Ratio = 5.08 (95% CI: ) p= No. at Risk Deferred ART 228 Immediate ART Continuous ART Intermittent ART Months No. at Risk Months Last CD4+ cell count (cells/ml) < > 500 Overall Event Rate * Event Rate * per 100 person years Emery S, et al. JID 2008; 197:

12 SMART: Non-AIDS event rates with Continuous vs. Intermittent ART Endpoint Continuous (n=2752) Intermittent (n=2720) HR (95% CI) P Value Any cause death ( ).007 Major CV, renal, or hepatic disease Fatal/nonfatal CV disease Fatal/nonfatal renal disease Fatal/nonfatal liver disease ( ) % 1.8% 1.6 ( ) % 0.3% 4.5 ( ) % 0.4% 1.4 ( ).46 Adapted from El-Sadr WM, et al. N Engl J Med 2006;355:

13 Immunodeficiency and Risk of Non-AIDS Defining Cancers Adjusted HR vs. non HIV* HIV Infected, CD4+ Cell Count, cells/mm 3 < P Value Any infection related <.001 Anal <.001 Hodgkin s lymphoma <.001 Oral/pharyngeal Infection unrelated Melanoma Lung Colorectal HIV-1 RNA levels not significantly associated with non-aids defining cancers * Adjusted for age, sex, smoking, overweight, alcohol/drug abuse, viral hepatitis; reference = uninfected cohort. P <.001 relative to uninfected. P <.05 relative to uninfected. Silverberg M, et al. CROI Abstract 28 and AIDS 2009.

14 Percent Difference Inflammatory markers are increased in ART-treated HIV+ patients vs. HIV Participants aged years hs-crp IL-6 D-dimer Cystatin-C Unadjusted Adjusted for age, gender, race Fully adjusted Adapted from Neuhaus J, et al. J Infect Dis. 2010;201(12):

15 Cumulative Probability of Event SMART: Hyaluronic Acid Levels in Hepatitis Coinfected Subjects Predict Non-AIDS Death Evaluation of impact of treatment interruption on liver fibrosis in SMART subjects with hepatitis coinfection (n=675) Baseline HA levels (>75 ng/ml) strong predictor of non- AIDS death in DC group Risk of Non-AIDS Death in HIV+, Hepatitis Coinfected According to Baseline HA and Treatment ARM DC Group, HA >75 DC Group, HA 75 VS Group, HA >75 VS Group, HA Months from Randomization DC =Drug Conservation; VS=Virologic Suppression Log rank test: P <.0001 (overall) P <.0001 (DC + HA >75 vs 3 other groups) P =0.35 (3 groups other than DC + HA >75) 15 Peters L et al.16th CROI; 2009; Montreal. Abstract 858.

16 HPTN 052: Treatment as Prevention Randomized, placebo-controlled efficacy and safety study 13 sites in Africa, Asia, Americas: N=1763 HIV-positive patients in relationship with HIVnegative partner 97% Heterosexual CD N= 886 immediate HAART N=877 Delayed HAART until CD4<250 (or AIDS) N=1 transmission 96% risk reduction N=27 transmissions All received ongoing safe sex education/condoms Study stopped four years early by DSMB (May 2011) All 28 transmissions genetically linked to the positive partner All on delayed arm now offered HAART Available at: Accessed May 12, 2011.

17 HPTN 052: Clinical Endpoints N=105 had primary clinical endpoint* Immediate: 40 Delayed: 65 HR: 0.6 (0.4,0.9) P=0.01 Extrapulmonary TB: largest difference favoring early treatment (P<0.002) Adverse events: Immediate: 24% Delayed: 5% Immediate Total (N=129) Tuberculosis Severe bacterial infection Death Chronic herpes simplex Bacterial pneumonia (recurrent) Esophageal candidiasis Delayed Grinstein B, et al. 6th IAS; Rome, Italy; July 17-20, Abst. MOAX0105, *Some pts had >1 event

18 START Study: Design HIV-infected individuals who are ART-naïve with CD4+ count > 500 cells/mm 3 Early ART group Initiate ART immediately following randomization N=2,000 Deferred ART group Defer ART until the CD4+ count declines to < 350 cells/mm 3 or AIDS develops N=2,000 Rate of primary endpoint in deferred group: 2.8 per 100 PY Non-AIDS : AIDS events = 4:1 Early ART reduces rate of primary endpoint by 28.8% 43% for AIDS and 24% for non-aids

19 What to Start?

20 Which Antiretrovirals: 2012 Currently Available in the US NRTIs Abacavir Didanosine NNRTIs Delavirdine Efavirenz PIs Atazanavir Darunavir Fusion inhibitors Enfuvirtide Emtricitabine Etravirine Fos-Amprenavir Lamivudine Nevirapine Indinavir Stavudine Nevirapine XR Lopinavir Entry inhibitors Tenofovir Rilpivirine Nelfinavir Maraviroc Zidovudine Ritonavir Saquinavir Tipranavir Integrase inhibitors Raltegravir

21 EACS Guidelines: Ten Initial Combination Regimens 1 drug in column A 1 NRTI combination A B REMARKS Recommended EFV NVP NNRTI Ritonavirboosted PI ATV/r DRV/r LPV/r Integrase Inhibitor RAL C = CONSIDER. D = DEFER. R = RECOMMENDED (October 2011) ABC/3TC or TDF/FTC TDF/FTC ABC/3TC or TDF/FTC TDF/FTC TDF/FTC co-formulated ABC/3TC co-formulated EFV/TDF/FTC co-formulated ATV/r: 300/100 mg qd DRV/r: 800/100 mg qd LPV/r: 400/100 mg bid or 800/200 mg qd RAL: 400 mg bid

22 EACS Guidelines: Initial Combination Regimen 1 drug in column A 1 NRTI combination A B REMARKS Alternative SQV/r FPV/r MVC ZDV/3TC ddl/3tc or FTC SQV/r: start with 500/100 mg then change to 1000/100 mg bid after one week FPV/r: 700/100 mg bid or 1400/200 mg qd ZDV/3TC co-formulated C = CONSIDER. D = DEFER. R = RECOMMENDED (October 2011)

23 2011 DHHS Guidelines: What to Start: Preferred Preferred Regimens: Regimens with optimal and durable efficacy, favorable tolerability and toxicity profile, and ease of use NNRTI: EFV/TDF/FTC EFV caution for women given risk of birth defects when EFV used in first trimester PI: ATV/r + TDF/FTC DRV/r (once daily) + TDF/FTC Int: RAL + TDF/FTC ATV/r should not be used in patient who require >20mg omeprazole equivalent per day RAL dosing BID Preferred Regimen for Pregnant Women LPV/r (twice daily) +ZDV/3TC Once-daily LPV/r is not recommended in pregnant women Comments: TDF should be used with caution in patients with renal insufficiency US Department of Health and Human Services Guidelines; Revised October 14, 2011 Available at:

24 2011 DHHS Guidelines: What to Start: Alternative Alternative Regimens - that are effective and tolerable but have potential disadvantages compared with preferred regimens. An alternative regimen may be the preferred regimen for some patients. NNRTI Based Regimens: EFV + ABC/3TC (BI) RPV/TDF/FTC (BI) RPV + ABC/3TC (BIII) Use RPV with caution in patients with pretreatment HIV RNA >100,000 copies/ml Use of proton pump inhibitors is contraindicated with RPV PI Based Regimens (alphabetically) ATV/r + ABC/3TC (BI) DRV/r + ABC/3TC (BIII) FPV/r (QD or BID) + ABC/3TC or TDF/FTC (BI) LPV/r (QD or BID) + ABC/3TC or TDF/FTC (BI) INSTI Based Regimen RAL + ABC/3TC (BIII) RAL dosed twice daily Comments for abacavir: Should not be used in patients who test positive for HLA-B5701 Use with caution in patients with known high risk of cardiovascular disease or with pretreatment HIV RNA >100,000 copies/ml US Department of Health and Human Services Guidelines; Revised October 14, 2011 Available at:

25 Probability of remaining free of virologic failure A5202: Two NRTIs plus EFV or ATV/r: Impact of baseline viral load and CD4 count ABC/3TC TDF/FTC 1 HIV RNA 100,000 c/ml HIV RNA < 100,000 c/ml n=98 35 VF n=78 23 VF n=80 19 VF n= VF n=39 6 VF n= VF n=23 5 VF n= VF 0.2 n=80 6 VF n=83 17 VF n=70 9 VF n= VF n=55 8 VF n= VF n=20 2 VF n= VF 0 CD4 (cells/mm 3 ) <50 50 to < to < Adapted from Grant P, et al. 18th CROI; Boston, MA; February 27-March 2, Abst

26 Relative risk (95% CI) D:A:D Study: NRTIs and risk of MI Recent Exposure*: yes/no ZDV ddi d4t 3TC ABC TDF #PYFU: 138,109 74,407 95, ,009 53,300 39,157 #MI: * Recent use=current or within the last 6 months. Adapted from Lundgren JD, et al. 16th CROI; Montreal, Canada; February 8-11, Abst. 42LB.

27 RR/year (95% CI) D:A:D Study: PIs/NNRTIs and Risk of MI Risk with Cumulative Exposure Effect of Adjustment for Latest Metabolic Factors 1.2 PI* NNRTI Lopinavir/r Indinavir 1.13 Primary model Dyslipidemia 1 Elevated blood pressure Diabetes mellitus Lipodystrophy 0.9 Glucose IDV NFV LPV/r SAQ NVP EFV #PYFU: 68,469 56,529 37,136 44,657 61,855 58,946 #MI: All above + lipid-lowering and antihypertensive RR of MI (95% CI) medication * Approximate test for heterogeneity: P=0.02 Lundgren JD, et al. 16th CROI; Montreal, Canada; February 8-11, Abst. 42LB.

28 The third drug : A review EFV never surpassed ATV/r, RAL: Noninferiority shown NVP: Fewer severe AEs, no CD4 restrictions PIs: ATV/r and DRV/r show advantages over LPV/r ATV/r: Less diarrhea (Castle) DRV/r: More forgiveness (Artemis) RAL Twice daily dosing

29 Absence of Primary Protease Mutations in First-Line Therapy With PI/r Study n NRTI backbone PI/r Week Genotypes Primary PI mutations d4t + 3TC LPV d4t + 3TC LPV d4t + 3TC LPV d4t + 3TC LPV TDF + 3TC LPV Solo ABC + 3TC FPV Staccato ddi + d4t SQV BMS d4t-xr + 3TC ATV ARTEMIS TDF + FTC LPV or DRV 96 NA 0 CASTLE TDF + FTC LPV or ATV * *in ATV/r arm 1. Gulick R, et al. 7th ICDTHI, 2004; Abstract P Kempf D, et al. J Inf Dis 2004;189:51; 3. Cahn P, et al. 1st IAS, 2001; Abstract Feinberg J, et al. 14th IAC, 2002; Abstract TuPeB Molina JM, et al. 15th IAC, 2004; Abstract WePeB MacManus S, et al. AIDS 2004;18:65; 7. Ananworanich J, et al. 3rd IAS, 2005; Abstract WePe4.4C12; 8. Malan N, et al. CROI 2006; Abstract 107LB. 9. Mills T, et al. 48th ICAAC/46th IDSA, 2008; Abstract H-1250c. 10. Molina J-M, et al. 48th ICAAC/46th IDSA, 2008; Abstract H-1250d.

30 Pooled ECHO/THRIVE: Week 48 Incidence of Treatment-emergent a RT mutationsby Baseline Viral Load Category 30 Incidence, n (%) RPV (N = 686) EFV (N = 682) All virologic failure with genotypic data b n = 62 n = 28 NNRTI RAM 39 (63) 15 (54) N(t)RTI RAM 42 (68) 9 (32) NNRTI and N(t)RTI RAM 37 (60) 8 (29) Baseline viral load 100K c/ml (RPV n=368), (EFV, n=330) n = 16 n =12 NNRTI RAM 61.6% (38) 51.5% (42) N(t)RTI RAM 7 (44) 2 (17) N(t)RTI RAM 1.9% 0.6% NNRTI and N(t)RTI RAM 5 (31) 1 (8) NNRTI and N(t)RTI RAM 1.4% 0.3% Baseline viral load >100K c/ml (RPV, n=318), (EFV, n=352) n = 46 n = 16 NNRTI RAM % (72) % (63) N(t)RTI RAM 3511% (76) 72% (44) NNRTI and N(t)RTI RAM 3210% (70) 72% (44) a Not present at screening or baseline and present at time of failure while on treatment. b At time of failure. Rimsky L, et al. IWHHC 2011; Los Cabos, Mexico. Abstract 9.

31 Cohen C, et al. 5th IAS; Cape Town, South Africa; July 19-22, 2009; Abst. MOPEB063. FOTO: 48 Week Results Five-days On, Two-days Off N=60 On TDF / FTC / EFV HIV RNA<50 X 6 months All drugs fully active Change to FOTO* N=30 TDF/FTC/EFV QD N=30 Continue FOTO* N=23 Rollover to FOTO* N=27 24 wk Extension/rollover 48 wk *FOTO=TDF/FTC/EFV five days on followed by 2 days off treatment per week

32 Patient Percent Cohen C, et al. 5th IAS; Cape Town, South Africa; July 19-22, 2009; Abst. MOPEB063. FOTO: Virologic Outcomes Percent < 50 copies/ml at each time point 97% 93% 100%* 86% 90% 90% No virologic failure all blips followed by subsequent suppression *Primary outcome Wk 24; p<0.001 to reject inferiority of FOTO vs. Daily strategy for maintaining suppression

33 VAT change from week 0 (%) A5224s: Change in Visceral Adipose Tissue CT Results: Mean percent change in VAT (ITT) NRTI Component Secondary Analysis NNRTI/PI Component Secondary Analysis P = 0.55 P = ATV/r average gain 1.8 kg trunk fat; EFV average gain 0.7 kg trunk fat. McComsey, G, et al. 18th CROI; Boston, MA; February 27-March 2, Abst. 77.

34 A5224s: Mean % Change in Lumbar Spine BMD P=0.004 P=0.035 * linear regression No significant interaction of NRTI and NNRTI/PI components (P=0.63) McComsey G, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 106LB.

35 Change in Calculated Creatinine Clearance, (ml/min) ACTG 5202: Median Change in Creatinine Clearance (Week 96, AT) 3TC/ABC FTC/TDF P = P < ATV/r EFV ATV/r EFV n= P values: ATV/r vs EFV Daar E et al. CROI Abstract 59LB.

36 Percentage of Patients Adherence: On time Pharmacy Refills by Number of Tablets per Day Single Tablet Regimen Multi-Tablet Regimen p< % have better adherence to STR p<0.01 p<0.01 p<0.01 N = <60% >60-79% 80-94% % Adherence to Antiretroviral Therapy Cohen CJ et al. ESPACOMP Nov 2011, Utrecht. Oral 315

37 Pooled ECHO/THRIVE: Adverse Event Summary at Week 96 RPV N=686 EFV N=682 Median treatment duration, weeks Incidence, n (%) All All p-value Discontinuations due to AEs 28 (4) 58 (9) Most common AEs of interest Any neurological AE 119 (17) 259 (38) < Dizziness 55 (8) 182 (27) < Any psychiatric AE 107 (16) 166 (24) < Abnormal dreams/nightmares 57 (8) 90 (13) Rash (any) 29 (4) 103 (15) < Cohen C, et al. IAS 2011, TULBPE032

38 Pooled ECHO and THRIVE: Week 48 Outcome by Adherence and Viral Load Adherent (>95%) Suboptimally Adherent BL VL <100K BL VL >100K BL VL <100K BL VL >100K RPV EFV RPV EFV RPV EFV RPV EFV Virologic Responder 95% 92% 87% 92% 47% 39% 31% 37% Virologic Failure 3% 4% 10% 4% 21% 11% 50% 17% Other D/C 2% 5% 2% 4% 31% 50% 19% 46% Rimsky L, et al. ICAAC 2010, H-1810.

39 Percent < 50 c/ml at Week 48 EVG/c/TDF/FTC vs. Two Preferred Regimens Virologic Responses (< 50c/mL) at Week 48 84% 88% 87% 90% 95% CI: (-1.6%, +8.8%) 95% CI: (-1.9, + 7.8%) Gilead press release, 8/15/2011 and 9/19/2011, accessed on

40 The Future: More ARVs, More Fixed Single Tablet Regimens NNRTIs EFV/FTC/TDF RPV/FTC/TDF Integrase inhibitors EVG/cobi/FTC/TDF DOL/ABC/3TC Protease inhibitor DRV/cobi/FTC/pro-TDF ATV/cobi

41 Stalemate? Or a Cure? may HIV flow from our blood into our history books. - William Jefferson Clinton 10 th Retrovirus Conf. Boston 2003

Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use

Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use Calvin Cohen MD Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston MA Learning

More information

Comprehensive Guideline Summary

Comprehensive Guideline Summary Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and

More information

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start

More information

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor

More information

Antiretroviral Therapy: What to Start

Antiretroviral Therapy: What to Start FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,

More information

HIV Treatment: State of the Art 2013

HIV Treatment: State of the Art 2013 HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

HIV - Therapy Principles

HIV - Therapy Principles HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV

More information

Update on Antiretroviral Treatment for HIV Infection 2008

Update on Antiretroviral Treatment for HIV Infection 2008 Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:

More information

Susan L. Koletar, MD

Susan L. Koletar, MD HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades

More information

Disclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv

Disclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases

More information

HIV Treatment: New and Veteran Drugs Classes

HIV Treatment: New and Veteran Drugs Classes HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are

More information

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role

More information

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts 1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion

More information

First-Line Antiretroviral Therapy for Treatment and Prevention:

First-Line Antiretroviral Therapy for Treatment and Prevention: First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When

More information

Susan L. Koletar, MD

Susan L. Koletar, MD HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades

More information

Pharmacological considerations on the use of ARVs in pregnancy

Pharmacological considerations on the use of ARVs in pregnancy Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl

More information

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,

More information

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H. Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community

More information

New Frontiers for Treatment Strategies for HIV Care

New Frontiers for Treatment Strategies for HIV Care New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:

More information

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and

More information

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

HIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko

HIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections

More information

HIV: Approach to the Treatment-Naïve Patient

HIV: Approach to the Treatment-Naïve Patient HIV: Approach to the Treatment-Naïve Patient Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Approach

More information

Rajesh T. Gandhi, M.D.

Rajesh T. Gandhi, M.D. HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000

More information

Criteria for Oral PrEP

Criteria for Oral PrEP Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates

More information

HIV in in Women Women

HIV in in Women Women HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732

More information

Selected Issues in HIV Clinical Trials

Selected Issues in HIV Clinical Trials Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic

More information

Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi

Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi 6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie

More information

Antiretroviral Treatment Strategies: Clinical Case Presentation

Antiretroviral Treatment Strategies: Clinical Case Presentation Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.

More information

Selected Issues in HIV Clinical Trials

Selected Issues in HIV Clinical Trials Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic

More information

Case # 1. Case #1 (cont d)

Case # 1. Case #1 (cont d) Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic

More information

Antiretroviral Drugs

Antiretroviral Drugs Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &

More information

Report Back from CROI 2010

Report Back from CROI 2010 Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco

More information

SELECTING THE BEST ART FOR EACH PATIENT

SELECTING THE BEST ART FOR EACH PATIENT SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May

More information

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,

More information

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity

More information

SA HIV Clinicians Society Adult ART guidelines

SA HIV Clinicians Society Adult ART guidelines SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with

More information

ARVs in Development: Where do they fit?

ARVs in Development: Where do they fit? The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker

More information

ART: The New, The Old and The Ugly

ART: The New, The Old and The Ugly ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside

More information

Didactic Series. CROI 2014 Update. March 27, 2014

Didactic Series. CROI 2014 Update. March 27, 2014 Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,

More information

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014

I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014 Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches

More information

13 th Conference on Retroviruses and Opportunistic Infections (CROI)

13 th Conference on Retroviruses and Opportunistic Infections (CROI) REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68

More information

Sasisopin Kiertiburanakul, MD, MHS

Sasisopin Kiertiburanakul, MD, MHS What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses

More information

Professor Jeffery Lennox

Professor Jeffery Lennox BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,

More information

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New

More information

Starting and Switching ART: 2016

Starting and Switching ART: 2016 Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus

More information

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in

More information

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which

More information

Professor José Arribas

Professor José Arribas 19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?

More information

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,

More information

What's new in the WHO ART guidelines How did markets react?

What's new in the WHO ART guidelines How did markets react? WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting

More information

Pharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005

Pharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers

More information

The next generation of ART regimens

The next generation of ART regimens The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state

More information

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection

More information

Josep Mallolas Hospital Clínic Barcelona

Josep Mallolas Hospital Clínic Barcelona Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV

More information

Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine

Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens

More information

Integrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University

Integrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless

More information

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of

More information

Somnuek Sungkanuparph, M.D.

Somnuek Sungkanuparph, M.D. HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor

More information

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,

More information

BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes

BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy START & other changes Contents Introduction & treatment aims Major changes When to start What to start BHIVA: what

More information

Second and third line paediatric ART strategies

Second and third line paediatric ART strategies Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor

More information

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures

More information

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,

More information

/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program

/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program /AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course

More information

The ART of Managing Drug-Drug Interactions in Patients with HIV

The ART of Managing Drug-Drug Interactions in Patients with HIV The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe

More information

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change

More information

Optimizing ARV For Women

Optimizing ARV For Women Optimizing ARV For Women Kathleen E. Squires, MD W Paul and Ida H Havens Professor of Infectious Diseases Director, Division of Infectious Diseases Sidney Kimmel Medical College of Thomas Jefferson University

More information

The 17th Conference on Retroviruses and Opportunistic Infections* ARV Therapies and Therapeutic Strategies A CME Newsletter

The 17th Conference on Retroviruses and Opportunistic Infections* ARV Therapies and Therapeutic Strategies A CME Newsletter * CROI 2010 * February 16-19, 2010 San Francisco, CA Course Director Calvin Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts Faculty Jürgen

More information

Central Nervous System Penetration of ARVs: Does it Matter?

Central Nervous System Penetration of ARVs: Does it Matter? NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15

More information

Antiretroviral Treatment 2014

Antiretroviral Treatment 2014 Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon

More information

Treatment strategies for the developing world

Treatment strategies for the developing world David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure

More information

ART Treatment. ART Treatment

ART Treatment. ART Treatment Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r

More information

The Eras of the HIV Epidemic

The Eras of the HIV Epidemic The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce

More information

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of

More information

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences

More information

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral

More information

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:

More information

HIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center

HIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center HIV Diagnosis and Management 2015 Update Faria Farhat, MD MedStar Washington Hospital Center Objectives Describe the epidemiology and pathogenesis of HIV infection Highlight HIV diagnosis algorithm and

More information

L infettivologia del 3 millennio: AIDS ed altro

L infettivologia del 3 millennio: AIDS ed altro L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie

More information

EACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director. Faculty

EACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director. Faculty EACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director John Bartlett, MD Professor, Johns Hopkins University School of Medicine Baltimore, Maryland

More information

16th Conference on Retroviruses and Opportunistic Infections ARV Therapies and Therapeutic Strategies A CME Newsletter

16th Conference on Retroviruses and Opportunistic Infections ARV Therapies and Therapeutic Strategies A CME Newsletter CROI 2009 8-11, February 2009 Montréal, Canada Course Director John Bartlett, MD Professor of Medicine Johns Hopkins University Baltimore, MD Faculty Rafael Campo, MD Professor of Clinical Medicine University

More information

Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI)

Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI) Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI) Gianni Di Perri Dept. de Maladies Infectieuses Universitè de Turin Ospedale Amedeo di Savoia Fusion inhibitors

More information

When to start: guidelines comparison

When to start: guidelines comparison The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count

More information

Fat redistribution on ARVs: dogma versus data

Fat redistribution on ARVs: dogma versus data Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach

More information

Actualización y Futuro en VIH

Actualización y Futuro en VIH Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral

More information

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

Didactic Series. Switching Regimens in the Setting of Virologic Suppression Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines

More information

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple

More information

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners

More information

HIV 101. Applications of Antiretroviral Therapy

HIV 101. Applications of Antiretroviral Therapy HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,

More information

Didactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012

Didactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012 Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council

More information

Antiretroviral Treatment (ART) of Adult HIV Infection*

Antiretroviral Treatment (ART) of Adult HIV Infection* Antiretroviral Treatment (ART) of Adult HIV Infection* Prepared by J Montaner for the BC- CfE Therapeutic Guidelines Committee of the British Columbia - Centre for Excellence in HIV/AIDS. *Based on M Thompson,

More information

Antiretroviral Therapy

Antiretroviral Therapy Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution

More information